Get started
Author

Kristian Windfeld

Observed names: K Windfeld, K. Windfeld, Windfeld K, Windfeld, K, Windfeld, K.
Institution: Genmab (Denmark)
ORCID: 0009-0004-3313-3923
Observed ORCID: 0009-0004-3313-3923
OpenAlex ID: A5006718167
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
2019 · Johann S de Bono, Nicole Concin, et al. · The Lancet Oncology · 237
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease
2018 · Alireza Atri, Lutz Frölich, et al. · JAMA · 167
PDF
Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial
2014 · David Wilkinson, Kristian Windfeld, et al. · The Lancet Neurology · 164
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
2019 · David S. Hong, Nicole Concin, et al. · Clinical Cancer Research · 135
PDF
A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
1999 · P Damsbo, P Clauson, et al. · Diabetes Care · 119
Hypoglycaemia with insulin aspart: a double‐blind, randomised, crossover trial in subjects with Type 1 diabetes
2004 · S. R. Heller, S. Colagiuri, et al. · Diabetic Medicine · 96
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
2012 · Myron S. Czuczman, Georg Hess, et al. · British Journal of Haematology · 58
PDF
Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL).
2010 · M. S. Czuczman, A. Viardot, et al. · Journal of Clinical Oncology · 10
O3–06–01: A clinical phase II study of Lu AE58054 added to stable donepezil treatment in patients with moderate Alzheimer's disease
2013 · David Wilkinson, Eskild Colding‐Jørgensen, et al. · Alzheimer s & Dementia · 8
PDF
Deep learning enhanced ALPS reveals genetic and environmental factors of brain glymphatic function
2026 · Cha Lin, Hao Wu, et al. · EBioMedicine · 6
Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al. · Cancer Research Communications · 6
PDF
Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study
2026 · Els Van Nieuwenhuysen, Ignace Vergote, et al. · Gynecologic Oncology · 3
PDF
1166P Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/GOG-3024/ENGOT-cx8 study
2025 · B.J. Monk, E. Van Nieuwenhuysen, et al. · Annals of Oncology · 2
Tisotumab vedotin (TV) in patients with previously treated recurrent or metastatic cervical cancer: Updated safety and efficacy results from the full cervical cohort of the phase II innova TV 201 study (NCT02001623)
2019 · D.S. Hong, H.T. Arkenau, et al. · Gynecologic Oncology · 2
Tisotumab vedotin in combination with carboplatin and pembrolizumab with or without bevacizumab in first-line recurrent or metastatic cervical cancer: First disclosure of arm H from the ENGOT-cx8/GOG-3024/innovaTV 205 study
2026 · Toon Van Gorp, Ignace Vergote, et al. · Gynecologic Oncology · 1
Brain MRI signatures across sex and CSF Alzheimer’s disease biomarkers
2025 · You Cheng, Yingnan He, et al. · Brain Communications · 1
PDF
Supplementary Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
2023 · David S. Hong, Nicole Concin, et al. · 1
PDF
A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort
2018 · N. Concin, I.B. Vergote, et al. · Annals of Oncology · 1
A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer.
2018 · Robert L. Coleman, Nicole Concin, et al. · Journal of Clinical Oncology · 1
Table S4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.
Data from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.
Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.
Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.
Table S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.
Table S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.
Works count: 46
Citation count: 1,018
H-index: 8
I10-index: 8
Year
Topic
Type